European Commission Approves New Dosing Regimen for Regeneron's Libtayo
Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for an alternative dosing regimen for its cancer therapy, Libtayo. The new protocol allows for a higher 700 mg dose, which is designed to improve patient convenience by reducing the frequency of clinic visits. This regulatory milestone is expected to significantly impact treatment administration by potentially halving infusion times for patients. By streamlining the delivery process, the new regimen aims to enhance patient adherence and reduce the logistical burden on healthcare providers within the European market.

Tickers: $REGN